Innate Pharma is laying off 30% of its workforce while putting its efforts and resources behind three of the company’s pipeline assets with the “highest potential” of delivering value both to patients and the biotech’s shareholders.
Innate Pharma is laying off 30% of its workforce while putting its efforts and resources behind three of the company’s pipeline assets with the “highest potential” of delivering value both to patients and the biotech’s shareholders.